Radiopharm Theranostics (RADX) vs Rocket One (RKTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket One (RKTO) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 59.1% versus a loss of 85.3%. Radiopharm Theranostics is the larger company by market cap ($16.5 million vs $16.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RADX | RKTO |
|---|---|---|
| Share price | $1.13 | $0.6612 |
| Market cap | $16.51M | $16.46M |
| 1-day change | +1.89% | +2.34% |
| YTD return | -78.74% | -34.74% |
| 1-year return | -85.27% | -59.11% |
| 5-year return | — | -97.77% |
| EPS (TTM) | $-3.64 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.25 | $2.45 |
| 52-week low | $1.00 | $0.489 |
| Distance from 52-week high | -93.04% | -73.01% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1401.28% | — |
| Average volume | 84.72K | 630.66K |
| Shares outstanding | 14.59M | 24.90M |
| Employees | 14 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RKTO has outperformed RADX by 26.2 percentage points over the past year.
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Rocket One
RKTO stock →Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
RADX vs RKTO FAQ
Which is bigger, Radiopharm Theranostics or Rocket One?
Radiopharm Theranostics (RADX) is larger, with a market capitalization of $16.51M compared with $16.46M for Rocket One (RKTO).
Which stock has performed better over the past year, RADX or RKTO?
RKTO returned -59.11% over the past 12 months, compared with -85.27% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are Radiopharm Theranostics and Rocket One in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.